Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Change in Account Payables (2016 - 2025)

Historic Change in Account Payables for Ani Pharmaceuticals (ANIP) over the last 14 years, with Q3 2025 value amounting to $13.8 million.

  • Ani Pharmaceuticals' Change in Account Payables rose 54709.32% to $13.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.6 million, marking a year-over-year increase of 5446.43%. This contributed to the annual value of $479000.0 for FY2024, which is 9365.73% down from last year.
  • As of Q3 2025, Ani Pharmaceuticals' Change in Account Payables stood at $13.8 million, which was up 54709.32% from $3.1 million recorded in Q2 2025.
  • Ani Pharmaceuticals' Change in Account Payables' 5-year high stood at $13.8 million during Q3 2025, with a 5-year trough of -$9.1 million in Q3 2022.
  • Over the past 5 years, Ani Pharmaceuticals' median Change in Account Payables value was $2.8 million (recorded in 2023), while the average stood at $2.4 million.
  • Within the past 5 years, the most significant YoY rise in Ani Pharmaceuticals' Change in Account Payables was 75323.0% (2022), while the steepest drop was 60232.2% (2022).
  • Over the past 5 years, Ani Pharmaceuticals' Change in Account Payables (Quarter) stood at $9.8 million in 2021, then increased by 3.02% to $10.1 million in 2022, then crashed by 72.38% to $2.8 million in 2023, then plummeted by 345.36% to -$6.8 million in 2024, then skyrocketed by 301.82% to $13.8 million in 2025.
  • Its last three reported values are $13.8 million in Q3 2025, $3.1 million for Q2 2025, and $5.5 million during Q1 2025.